Company: TELO
Filing Date: 2025-02-04
Form Type: 10-K
Source: 0001493152-25-004872
Chunk: 129

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-04
Form: 10-K
Item: Item 9C
Chunk 129
---
daq and SEC rules and regulations, including Rule 10A-3(b)(1) under the Exchange Act.
Each member of our audit committee meets the financial literacy requirements of the listing standards of Nasdaq. In addition, our board
of directors has determined that Mr. Whalen is an audit committee financial expert within the meaning of Item 407(d) of Regulation S-K
under the Securities Act.

58

The
audit committee’s main purpose is to oversee our corporate accounting and financial reporting process. Our audit committee will
be responsible for, among other things:

    ●
    selecting
    a qualified firm to serve as the independent registered public accounting firm to audit our financial statements;

    ●
    helping
    to ensure the independence and performance of the independent registered public accounting firm;

    ●
    discussing
    the scope and results of the audit with the independent registered public accounting firm, and reviewing, with management and the
    independent registered public accounting firm, our interim and year-end results of operations;

    ●
    developing
    procedures for employees to submit concerns anonymously about questionable accounting or audit matters;

    ●
    reviewing
    our policies on risk assessment and risk management;

    ●
    reviewing
    related party transactions;

    ●
    reviewing
    and pre-approving, as required, all audit and all permissible non-audit services to be performed by the independent registered public
    accounting firm; and

    ●
    assisting
    our board of directors in monitoring the performance of our internal audit function.

Our
audit committee operates under a written charter that satisfies the applicable rules and regulations of the SEC and the listing standards
of Nasdaq, a copy of which will be available on our website at www.telomirpharma.com.

Compensation
Committee

The
Compensation Committee was initially established upon the effectiveness of our initial public offering on February 9, 2024. As of December
2024, the Compensation Committee consists of Dr. Matthew P. Del Giudice (Chair), and Mr. Edward MacPherson. Dr. Matthew P. Del Giudice
succeeded Talhia Tuck as Chair of the Compensation Committee following her resignation, along with Bradley Kroenig, from the Board of
Directors in August 2024. Each member of the committee meets the requirements for independence under the listing standards of Nasdaq
and SEC rules and regulations. Each member is also a non-employee director, as defined pursuant to